EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections

Jacinta O Pinho iD, Magda Ferreira, Mariana Coelho iD, Sandra N Pinto iD, Sandra I Aguiar, Maria Manuela Gaspar iD

Pharmaceuticals · 08.04.2024 · 17 (4) · 470

DOI: 10.3390/ph17040470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 08.04.2024. Verfasst von Jacinta O Pinho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e Tecnologia, Phospholipid Research Center, Research Unit Institute for Bioengineering and Biosciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methicillin-resistant Staphylococcus aureus (M RSA) infections, in particular biofilm-organized bacteria, remain a clinical challenge and a serious health problem. Rifabutin (RFB), an antibiotic of the rifamycins class, has shown in previous work excellent anti-staphylococcal activity. Here, we proposed to load RFB in liposomes aiming to promote the accumulation of RFB at infected sites and consequently enhance the therapeutic potency. Two clinical isolates of MRSA, MRSA-C1 and MRSA-C2, were used to test the developed formulations, as well as the positive control, vancomycin (VCM). RFB in free and liposomal forms displayed high antibacterial activity, with similar potency between tested formulations. In MRSA-C1, minimal inhibitory concentrations (MIC) for Free RFB and liposomal RFB were 0.009 and 0.013 μg/mL, respectively. Minimum biofilm inhibitory concentrations able to inhibit 50% biofilm growth (MBIC50) for Free RFB and liposomal RFB against MRSA-C1 were 0.012 and 0.008 μg/mL, respectively. Confocal microscopy studies demonstrated the rapid internalization of unloaded and RFB-loaded liposomes in the bacterial biofilm matrix. In murine models of systemic MRSA-C1 infection, Balb/c mice were treated with RFB formulations and VCM at 20 and 40 mg/kg of body weight, respectively. The in vivo results demonstrated a significant reduction in bacterial burden and growth index in major organs of mice treated with RFB formulations, as compared to Control and VCM (positive control) groups. Furthermore, the VCM therapeutic dose was two fold higher than the one used for RFB formulations, reinforcing the therapeutic potency of the proposed strategy. In addition, RFB formulations were the only formulations associated with 100% survival. Globally, this study emphasizes the potential of RFB nanoformulations as an effective and safe approach against MRSA infections.

Schlagwörter

Stichwörter der Autor:innen

Staphylococcus aureus infectionbiofilmclinical isolatesliposomesmethicillin-resistant bacteriaplanktonic bacteriarifabutintherapeutic strategy

Autor:innen und Institutionen

  • Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.
  • Center for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, Universidade de Lisboa, 1300-477 Lisboa, Portugal.
  • Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), Faculty of Veterinary Medicine, Universidade de Lisboa, 1300-477 Lisboa, Portugal.
  • iBB-Institute for Bioengineering and Biosciences and Associate Laboratory i4HB-Institute for Health and Bioeconomy at Department of Bioengineering, Instituto SuperiorTécnico, Universidade de Lisboa, 1049-001 Lisboa, Por…
  • IBEB, Institute of Biophysics and Biomedical Engineering, Faculty of Sciences, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.

ORCID-Profile: Jacinta O Pinho, Mariana Coelho, Sandra N Pinto, Maria Manuela Gaspar

Förderung

  • Fundação para a Ciência e Tecnologia
  • Phospholipid Research Center
  • Research Unit Institute for Bioengineering and Biosciences
  • Institute for Health and Bioeconomy, i4HB
  • DENDRICARE
  • research infrastructure PPBI-POCI-01-0145-FEDER-022122

Zitieren

APA

Pinho, J. O., Ferreira, M., Coelho, M., Pinto, S. N., Aguiar, S. I., & Gaspar, M. M. (2024). Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections. Pharmaceuticals, 17(4), 470. https://doi.org/10.3390/ph17040470

Vancouver

Pinho JO, Ferreira M, Coelho M, Pinto SN, Aguiar SI, Gaspar MM. Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections. Pharmaceuticals. 2024;17(4):470. doi:10.3390/ph17040470

BibTeX
@article{Pinho2024,
  author = {Pinho, Jacinta O and Ferreira, Magda and Coelho, Mariana and Pinto, Sandra N and Aguiar, Sandra I and Gaspar, Maria Manuela},
  title = {Liposomal Rifabutin—A Promising Antibiotic Repurposing Strategy against Methicillin-Resistant Staphylococcus aureus Infections},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {4},
  pages = {470},
  doi = {10.3390/ph17040470}
}
Kostenlos starten →